Iovance Biotherapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-47.3M | $-79.0M | $-71.9M | $-91.3M | $-111.7M | $-116.2M | $-78.6M | $-83.5M |
| Depreciation & Amortization | $9.5M | $2.8M | $-2.1M | $9.0M | $3.4M | $2.6M | $2.3M | $3.0M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $5.7M | $5.7M | $6.1M | $5.8M | $5.7M | $5.5M | $10.7M | $5.5M |
| Stock-Based Compensation | $11.7M | $11.3M | $11.8M | $11.9M | $14.9M | $22.9M | $31.0M | $31.0M |
| Net Cash from Operating Activities | $-60.8M | $-72.1M | $-52.6M | $-78.7M | $-67.4M | $-103.7M | $-73.3M | $-59.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $5.4M | $6.6M | $9.3M | $10.8M | $7.5M | $6.2M | $4.2M | $2.3M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-74.1M | $11.4M | $775.0K | $17.0M | $13.8M | $15.9M | $23.7M | $-48.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $49.3M | $94.3M | $56.2M | $88.1M | $13.2M | $143.3M | $2.3M | $42.0M |
| Net Change in Cash | $-85.7M | $33.4M | $5.0M | $25.7M | $-39.6M | $56.0M | $-48.5M | $-64.6M |
| Free Cash Flow | $-66.3M | $-78.7M | $-61.9M | $-89.5M | $-74.9M | $-109.9M | $-77.5M | $-61.3M |